-
1.发明公开
公开(公告)号：EP2288727A1
公开(公告)日：2011-03-02
申请号：EP09747492.8
申请日：2009-05-13
发明人： BAKER, Joffre, B. , WATSON, Drew , MADDALA, Tara , SHAK, Steven , MAURO, David, J. , FORD, Shirin, K.
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
摘要翻译： 本发明提供了有助于确定个体中的表达EGFR的癌症是否是EGFR抑制剂响应性癌症的方法和组合物，以及用于确定具有表达EGFR的癌症的患者将显示对 一种EGFR抑制剂疗法。 该方法通常涉及确定与EGFR抑制剂响应性相关的基因产物的标准化表达水平。
-
2.发明授权
公开(公告)号：EP2288727B1
公开(公告)日：2013-07-10
申请号：EP09747492.8
申请日：2009-05-13
发明人： BAKER, Joffre, B. , WATSON, Drew , MADDALA, Tara , SHAK, Steven , MAURO, David, J. , FORD, Shirin, K.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
-
公开(公告)号：EP3179393B1
公开(公告)日：2020-07-08
申请号：EP16191856.0
申请日：2013-01-28
申请人： Genomic Health, Inc.
-
4.发明公开METHOD TO USE GENE EXPRESSION TO DETERMINE LIKELIHOOD OF CLINICAL OUTCOME OF RENAL CANCER 审中-公开利用基因表达的抑制，用于确定肾癌的临床开发的可能性的方法
公开(公告)号：EP3029155A2
公开(公告)日：2016-06-08
申请号：EP15203193.6
申请日：2011-01-07
申请人： Genomic Health, Inc.
发明人： SHAK, Steven , GODDARD, Audrey , KNEZEVIC, Dejan , BAKER, Joffre , KIEFER, Michael C. , MADDALA, Tara , BAEHNER, Frederick L. , COWENS, Wayne
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , G01N33/57438 , G06F19/00 , G06F19/10 , G06N7/005 , G16H50/20
摘要： The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
-
5.发明公开
公开(公告)号：EP2598659A2
公开(公告)日：2013-06-05
申请号：EP11813024.4
申请日：2011-07-25
申请人： Genomic Health, Inc.
发明人： SHAK, Steven , BAEHNER, Frederick, L. , MADDALA, Tara , LEE, Mark , PELHAM, Robert, J. , COWENS, Wayne , CHERBAVAZ, Diana , KIEFER, Michael, C. , CRAGER, Michael , GODDARD, Audrey , BAKER, Joffre, B.
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178 , G06F19/00
摘要： Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
-
6.发明公开
公开(公告)号：EP3831964A2
公开(公告)日：2021-06-09
申请号：EP20210111.9
申请日：2011-01-07
申请人： Genomic Health, Inc.
发明人： SHAK, Steven , GODDARD, Audrey , KNEZEVIC, Dejan , BAKER, Joffre B. , KIEFER, Michael C. , MADDALA, Tara , BAEHNER, Frederick L. , COWENS, Wayne
IPC分类号： C12Q1/6886
摘要： The present disclosure provides gene and gene sets, the expression of which is important in the classification (e.g. determining the grade or stage of the tumor, or determining the presence of necrosis or nodal invasion) and/or prognosis (e.g. of recurrence) of cancer, in particular of renal cell carcinoma.
-
7.发明公开GENE EXPRESSION PROFILE ALGORITHM AND TEST FOR DETERMINING PROGNOSIS OF PROSTATE CANCER 审中-公开基因表达谱简介及测定前列腺癌预后的实验研究
公开(公告)号：EP3179393A2
公开(公告)日：2017-06-14
申请号：EP16191856.0
申请日：2013-01-28
申请人： Genomic Health, Inc.
发明人： SHAK, Steve , LEE, Mark , NOVOTNY, William , MADDALA, Tara , CRAGER, Michael , CHERBAVAZ, Diana , PELHAM, Robert , MILLWARD, Carl L. , KNEZEVIC, Dejan
摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
摘要翻译： 本发明提供了基于算法的分子测定法，其涉及从获自前列腺癌患者的生物样品测量基因或其共表达基因的表达水平。 可将基因分组为功能基因亚组，用于计算可用于预测前列腺癌患者临床结果可能性的定量评分。
-
8.发明公开METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER 审中-公开方法使用确定前列腺癌的预后基因表达的抑制
公开(公告)号：EP3147373A1
公开(公告)日：2017-03-29
申请号：EP16195347.6
申请日：2011-07-25
申请人： Genomic Health, Inc.
发明人： SHAK, Steven , BAEHNER, Frederick L. , MADDALA, Tara , LEE, Mark , PELHAM, Robert , COWENS, Wayne , CHERBAVAZ, Diana , KIEFER, Michael C. , CRAGER, Michael , GODDARD, Audrey , BAKER, Joffre B.
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178 , G06F19/00
摘要： Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
摘要翻译： 分子检测确实涉及从前列腺癌患者获得的生物样品的生物标记物的预后，或共同过表达的生物标志物的表达水平的测量，并且所测量的表达水平的分析，以提供关于信息用于所述患者的可能的预后，和似然确实 所述患者将有前列腺癌的复发，或至肿瘤通过临床结果或融合TMPRSS2状态的似然性，在提供分类。
-
9.发明授权
公开(公告)号：EP2598659B1
公开(公告)日：2015-03-11
申请号：EP11813024.4
申请日：2011-07-25
申请人： Genomic Health, Inc.
发明人： SHAK, Steven , BAEHNER, Frederick, L. , MADDALA, Tara , LEE, Mark , PELHAM, Robert, J. , COWENS, Wayne , CHERBAVAZ, Diana , KIEFER, Michael, C. , CRAGER, Michael , GODDARD, Audrey , BAKER, Joffre, B.
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178 , G06F19/00
摘要： Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
-
10.发明公开
公开(公告)号：EP3739595A3
公开(公告)日：2021-01-27
申请号：EP20180564.5
申请日：2013-01-28
申请人： Genomic Health, Inc.
发明人： SHAK, Steve , LEE, Mark , NOVOTNY, William , MADDALA, Tara , CRAGER, Michael , CHERBAVAZ, Diana , PELHAM, Robert , MILLWARD, Carl L. , KNEZEVIC, Dejan
摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.037 秒)
